<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03122652</url>
  </required_header>
  <id_info>
    <org_study_id>14-PP-11</org_study_id>
    <nct_id>NCT03122652</nct_id>
  </id_info>
  <brief_title>Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome</brief_title>
  <acronym>TERIS</acronym>
  <official_title>Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) is a common cause of severe neurological disability in young adults,&#xD;
      resulting from an autoimmune interruption of both myelin and axons within the central nervous&#xD;
      system (CNS). The diagnosis is made by fulfilling both spatial criteria, by meeting the&#xD;
      requisite number of lesions within the brain or spinal cord, along with criteria for time, by&#xD;
      demonstrating a history of at least a second clinical attack or the development of a new MS&#xD;
      lesion on MRI after the seminal neurological event. In the case of MS, healthy individuals&#xD;
      who do not exhibit signs of neurological dysfunction commonly have brain MRI studies&#xD;
      performed for a reason other than an evaluation for MS that reveal unexpected anomalies&#xD;
      highly suggestive of demyelinating plaques given their size, location, and morphology. These&#xD;
      healthy subjects lack symptomatology suggestive of MS and fulfill formal criteria for&#xD;
      radiologically isolated syndrome (RIS), a recently described MS subtype that expands upon the&#xD;
      phenotype of at-risk individuals for future demyelinating events. The discovery of such&#xD;
      anomalies creates intersecting neuro-ethical, legal, social, and practical medical management&#xD;
      quandaries and is, therefore, of both immediate and long-term clinical significance. Despite&#xD;
      advancements in the characterization of RIS subjects, and in our understanding of risk&#xD;
      factors for initial symptom development, the effect of treatment on such cases remain&#xD;
      unclear.&#xD;
&#xD;
      The purpose of this investigation is to systematically study the efficacy of Teriflunomide in&#xD;
      those individuals who possess incidental white matter anomalies within the brain and&#xD;
      following a MRI study that is performed for a reason other than for the evaluation of MS.&#xD;
&#xD;
      RIS subjects are frequently exposed to disease modifying therapies despite the lack of&#xD;
      scientific literature supporting the use of such treatments. Earlier treatment intervention&#xD;
      may extend the time to the first acute or progressive clinical event resulting from CNS&#xD;
      demyelination and reduce radiological progression. In addition, early treatment may result in&#xD;
      more profound effects on reducing disability progression long-term.&#xD;
&#xD;
      The primary outcome measure for this trial is the time to the first acute or progressive&#xD;
      neurological event resulting from CNS demyelination.&#xD;
&#xD;
      This study will include RIS subjects from the Europe who fulfill 2009 RIS Criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 25, 2017</start_date>
  <completion_date type="Anticipated">October 24, 2022</completion_date>
  <primary_completion_date type="Actual">February 5, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to the first acute or progressive neurological event resulting from CNS demyelination.</measure>
    <time_frame>Week 96</time_frame>
    <description>Acute neurological event: The development of an acute neurological episode localized to the optic nerve, brainstem, cerebellum, spinal cord, or long sensory or motor tracts, lasting &gt; 24 hours followed by a period of symptom improvement.&#xD;
Progressive event: The onset of a clinical symptom (e.g. leg weakness) with the temporal profile revealing at least a 12-month progression of neurological deficits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New or enlarging T2 lesions</measure>
    <time_frame>Week 48</time_frame>
    <description>Number of new or enlarging T2 lesions on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New or enlarging T2 lesions</measure>
    <time_frame>Week 96</time_frame>
    <description>Number of new or enlarging T2 lesions on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New contrast enhancing lesions</measure>
    <time_frame>Week 48</time_frame>
    <description>New contrast enhancing lesions on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New contrast enhancing lesions</measure>
    <time_frame>Week 96</time_frame>
    <description>New contrast enhancing lesions on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New T2-lesion volumes</measure>
    <time_frame>Week 48</time_frame>
    <description>New T2-lesion volumes on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New T2-lesion volumes</measure>
    <time_frame>Week 96</time_frame>
    <description>New T2-lesion volumes on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain atrophy</measure>
    <time_frame>Week 96</time_frame>
    <description>Brain atrophy on MRI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Terifunomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriflunomide 14 MG Oral Tablet [Aubagio]</intervention_name>
    <description>1 tablet once a day</description>
    <arm_group_label>Terifunomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>1 tablet once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females of all ages(&gt;18 years and &lt;65 years) meeting 2009 RIS criteria:&#xD;
&#xD;
             A. The presence of incidentally identified CNS white matter anomalies meeting the&#xD;
             following MRI criteria:&#xD;
&#xD;
               1. Ovoid, well-circumscribed, and homogeneous foci observed with or without&#xD;
                  involvement of the corpus callosum&#xD;
&#xD;
               2. T2 hyperintensities measuring ≥3 mm and fulfilling Barkhof criteria (at least&#xD;
                  three out of four) for dissemination in space&#xD;
&#xD;
               3. Anomalies not following a clear vascular pattern&#xD;
&#xD;
               4. Structural neuroimaging abnormalities identified not explained by another disease&#xD;
                  process B. No historical accounts of remitting clinical symptoms consistent with&#xD;
                  neurological dysfunction C. The MRI anomalies do not account for clinically&#xD;
                  apparent impairments in social, occupational, or generalized area of functioning&#xD;
                  D. The MRI anomalies are not due to the direct physiological effects of&#xD;
                  substances (recreational drug use, toxic exposure) or a medical condition E.&#xD;
                  Exclusion of individuals with MRI phenotypes suggestive of leukoaraiosis or&#xD;
                  extensive white matter changes lacking clear involvement of the corpus callosum&#xD;
                  F. The CNS MRI anomalies are not better accounted for by another disease process&#xD;
&#xD;
          2. Identified RIS cases with the initial MRI demonstrating anomalies suggestive of&#xD;
             demyelinating disease dated ≥ 2009&#xD;
&#xD;
          3. Incidental anomalies identified on MRI of the brain or spinal cord with the primary&#xD;
             reason for the acquired MRI resulting from an evaluation of a process other than MS&#xD;
&#xD;
          4. Affiliation to the social security system&#xD;
&#xD;
          5. Subjects of reproductive potential are eligible only if the following applies:&#xD;
&#xD;
               -  Women of childbearing potential (WOCBP):Must have a negative serum pregnancy test&#xD;
                  at Visit 1 (Screening) and negative urine pregnancy test at Visit 2 (Baseline);&#xD;
&#xD;
               -  Must be agree to undertake 1 monthly urine pregnancy tests during the study and&#xD;
                  up to 6 weeks after the first of two tests showing teriflunomide plasma level&#xD;
                  &lt;0.02 mg/L;&#xD;
&#xD;
               -  Must agree to use reliable methods of contraception from Visit 1 until 6 weeks&#xD;
                  after the first oft wo tests showing teriflunomide plasma level &lt;0.02 mg/L.&#xD;
&#xD;
        Fertile male subjects participating in the study who are sexually active with WOCBP:&#xD;
&#xD;
        - Must agree to use condom during the treatment period and for an additional 6 weeks after&#xD;
        the first oft wo tests showing teriflunomide plasma level &lt;0.02 mg/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to the active substance or to any of the excipients listed in section&#xD;
             6.1 of summary of product characteristics (SmPC).&#xD;
&#xD;
          2. Patients with severe hepatic impairment (Child-Pugh class C).&#xD;
&#xD;
          3. Patients with severe immunodeficiency states, e.g. AIDS.&#xD;
&#xD;
          4. Patients with significantly impaired bone marrow function or significant anaemia,&#xD;
             leucopenia, neutropenia or thrombocytopenia.&#xD;
&#xD;
          5. Patients with severe active infection until resolution.&#xD;
&#xD;
          6. Patients with severe renal impairment undergoing dialysis.&#xD;
&#xD;
          7. Patients with severe hypoproteinaemia, e.g. in nephrotic syndrome.&#xD;
&#xD;
          8. Lactating or pregnant women&#xD;
&#xD;
          9. Subjects wishing to parent a child during the study&#xD;
&#xD;
         10. Incomplete medical history or radiological data&#xD;
&#xD;
         11. History of remitting clinical symptoms consistent with multiple sclerosis lasting &gt; 24&#xD;
             hours prior to CNS imaging revealing anomalies suggestive of MS&#xD;
&#xD;
         12. History of paroxysmal symptoms associated with MS (i.e. Lhermitte's or Uhthoff's&#xD;
             phenomena)&#xD;
&#xD;
         13. CNS MRI anomalies are better accounted for by another disease process&#xD;
&#xD;
         14. The subject is unwilling or unable to comply with the requirements of the study&#xD;
             protocol&#xD;
&#xD;
         15. Exposure to a disease modifying therapy within the past 3 months&#xD;
&#xD;
         16. Exposure to high-dose glucocorticosteroid treatment within the past 30 days&#xD;
&#xD;
         17. Vulnerable subject (such as deprived from freedom) as defined in Section 1.61 of&#xD;
             International Conference on Harmonisation (ICH) Guideline for Good Clinical Practice&#xD;
             (GCP: Individuals whose willingness to volunteer in a clinical trial may be unduly&#xD;
             influenced by the expectation, whether justified or not, of benefits associated with&#xD;
             participation, or of a retaliatory response from senior members of a hierarchy in case&#xD;
             of refusal to participate. Examples are members of a group with a hierarchical&#xD;
             structure, such as medical, pharmacy, dental, and nursing students, subordinate&#xD;
             hospital and laboratory personnel, employees of the pharmaceutical industry, members&#xD;
             of the armed forces, and persons kept in detention. Other vulnerable subjects include&#xD;
             patients with incurable diseases, persons in nursing homes, unemployed or impoverished&#xD;
             persons, patients in emergency situations, ethnic minority groups, homeless persons,&#xD;
             nomads, refugees, minors, and those incapable of giving consent.)&#xD;
&#xD;
         18. Participation in another clinical trial of an investigational medicinal product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine LEBRUN-FRENAY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mustafa Kemal University</name>
      <address>
        <city>Antakya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uludag University School of Medicine</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty</name>
      <address>
        <city>İzmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kocaeli University School of Medicine</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayis University, Faculty of Medicine</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Martinique</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiologically Isolated Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriflunomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

